Table 3.
All, % (95% CI) | Targeted therapy, % (95% CI) | Chemoimmunotherapy, % (95% CI) | P | |
---|---|---|---|---|
3-y OS | 73 (64, 80) | 87 (68, 95) | 69 (58, 78) | .22 |
3-y PFS | 61 (51, 70) | 72 (52, 85) | 58 (46, 68) | .3 |
3-y NRM | 14 (8, 21) | 7 (1, 19) | 17 (9, 26) | .2 |
3-y relapse | 24 (17, 33) | 21 (8, 38) | 26 (17, 36) | .88 |
6-mo grade III-IV acute GVHD | 9 (5, 16) | 13 (4, 28) | 7.7 (3, 15) | .5 |
1-y chronic GVHD | 48 (38, 57) | 57 (37, 73) | 45 (34, 56) | .47 |